Jubilant Ingrev.

Why is Jubilant Ingrevia Ltd falling/rising?

As of 19-Jun, Jubilant Ingrevia Ltd's stock is declining, with a -1.1% change and a total drop of -12.08% over the past month. The stock is underperforming its sector and has seen reduced investor interest, indicating a bearish trend despite the company's strong debt servicing ability.

As of 19-Jun, Jubilant Ingrevia Ltd's stock price is currently falling, as indicated by a change of -7.1, or -1.1%. The stock has been underperforming, having lost value for the last three consecutive days, resulting in a total decline of -1.89% during this period. Additionally, the stock's performance today has underperformed its sector by -1.83%. <BR><BR>Over the past month, the stock has experienced a significant decline of -12.08%, contrasting with a modest gain of +2.13% in the Sensex during the same timeframe. Furthermore, the stock's current price is lower than its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Investor participation has also decreased, with delivery volume dropping by -68.11% compared to the 5-day average, suggesting reduced interest from investors. Despite these negative indicators, the company maintains a strong ability to service its debt and has a low Debt to EBITDA ratio, which may provide some stability. However, the overall sentiment reflected in the stock's recent performance points to a downward trend.

Which are the latest news on Jubilant Ingrev.?

What does Jubilant Ingrev. do?

Jubilant Ingrevia Ltd is a small-cap company in the specialty chemicals industry, incorporated in 2019, with recent quarterly net sales of ₹1,179 Cr and net profit of ₹86 Cr as of March 2026. Key metrics include a P/E ratio of 34.00 and a market cap of ₹9,975 Cr.

Overview: <BR>Jubilant Ingrevia Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History: <BR>Jubilant Ingrevia Limited was incorporated as a Public Limited Company in 2019. The company changed its name from 'Jubilant LSI Limited' to 'Jubilant Ingrevia Limited' on October 16, 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,179 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 86 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 9,975 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.80% <BR>Debt Equity: 0.19 <BR>Return on Equity: 9.19% <BR>Price to Book: 3.20 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Jubilant Ingrev.?

As of 10th June, Jubilant Ingrevia Ltd has a market capitalization of 9,975.00 Cr, with recent net sales of 4,388.24 Cr and a net profit of 277.91 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Jubilant Ingrevia Ltd has a market capitalization of 9,975.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,388.24 Cr, while the sum of Net Profit for the same period is 277.91 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,927.08 Cr and Total Assets valued at 5,015.12 Cr.

Who are in the management team of Jubilant Ingrev.?

The management team of Jubilant Ingrev includes Shyam S Bhartia (Chairman), Hari S Bhartia (Co-Chairman), Rajesh Srivastava, Deepak Jain, and Chandan Singh Sengar (Managing Directors), along with several Independent and Non-Executive Directors. This diverse leadership team brings a wealth of expertise to the company.

The management team of Jubilant Ingrev includes the following individuals:<BR><BR>1. **Shyam S Bhartia** - Chairman & Non-Executive Director<BR>2. **Hari S Bhartia** - Co-Chairman / Non-Executive Director<BR>3. **Rajesh Srivastava** - Managing Director & CEO<BR>4. **Mr. Deepak Jain** - Managing Director & CEO<BR>5. **Mr. Chandan Singh Sengar** - Whole Time Director & CEO<BR><BR>Additionally, the Board of Directors features several Independent Non-Executive Directors:<BR><BR>- **S K Roongta**<BR>- **Sudha Pillai**<BR>- **Arun Seth**<BR>- **Pradeep Banerjee**<BR>- **Siraj Azmat Chaudhry**<BR>- **Ameeta Sonjoy**<BR><BR>There are also Non-Executive Directors:<BR><BR>- **Priyavrat Bhartia**<BR>- **Arjun Shanker Bhartia**<BR><BR>This diverse team brings a range of expertise to the company's leadership.

Who are the peers of the Jubilant Ingrev.?

Jubilant Ingrev.'s peers include Anupam Rasayan, Fine Organic, BASF India, Vinati Organics, Privi Speci., Alkyl Amines, Clean Science, Elantas Beck, Balaji Amines, and Archean Chemical. Its 1-year return is -8.43%, better than BASF India's -34.30% but lower than Privi Speci.'s 40.48%.

Peers: The peers of Jubilant Ingrev. are Anupam Rasayan, Fine Organic, BASF India, Vinati Organics, Privi Speci., Alkyl Amines, Clean Science, Elantas Beck, Balaji Amines, and Archean Chemical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fine Organic and Clean Science, while Good management risk is found at BASF India, Vinati Organics, Privi Speci., Jubilant Ingrev., Alkyl Amines, Elantas Beck, and Archean Chemical. Below Average management risk is noted at Anupam Rasayan and Balaji Amines. Average growth is seen at Anupam Rasayan and Privi Speci., while Below Average growth is present at BASF India, Vinati Organics, Jubilant Ingrev., Alkyl Amines, Clean Science, Elantas Beck, Balaji Amines, and Archean Chemical. Excellent capital structure is held by Fine Organic, BASF India, Vinati Organics, Jubilant Ingrev., Alkyl Amines, Clean Science, Elantas Beck, and Balaji Amines, while Average capital structure is noted at Anupam Rasayan and Below Average at Privi Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Privi Speci. at 40.48%, while the lowest is BASF India at -34.30%. Jubilant Ingrev.'s 1-year return is -8.43%, which is higher than BASF India but lower than Privi Speci. Additionally, Clean Science and Archean Chemical have negative six-month returns.

Should I buy, sell or hold Jubilant Ingrevia Ltd?

Are Jubilant Ingrevia Ltd latest results good or bad?

Jubilant Ingrevia Ltd's latest Q4 FY26 results are strong, with a net profit increase of 84.31% quarter-on-quarter and net sales growth of 12.16%. However, concerns about long-term growth and historical performance lead to a cautious market outlook.

Jubilant Ingrevia Ltd's latest results for Q4 FY26 can be considered good, showcasing a significant operational turnaround. The company reported a net profit of ₹86.44 crores, which is an impressive 84.31% increase quarter-on-quarter and a 16.73% rise year-on-year. Additionally, net sales reached ₹1,178.65 crores, marking a 12.16% increase from the previous quarter and a similar 12.12% growth year-on-year.<BR><BR>The operating margin also improved to 13.94%, reflecting a positive trend in profitability. This strong performance indicates effective cost management and operational leverage, which is encouraging for investors.<BR><BR>However, it's important to note that despite these positive quarterly results, there are concerns regarding the company's long-term growth trajectory. Jubilant Ingrevia has faced challenges over the past five years, with a negative compound annual growth rate in sales and weak return on equity compared to its peers. The market's reaction to the results has been cautious, as evidenced by the stock's price movement post-announcement.<BR><BR>Overall, while the latest quarterly results are strong, the company's historical performance and market valuation suggest a more cautious outlook moving forward.

Has Jubilant Ingrevia Ltd declared dividend?

Yes, Jubilant Ingrevia Ltd has declared a dividend of 250% (₹2.5 per share) with an ex-date of July 25, 2025. While recent total returns have been negative over shorter periods, the company has shown positive returns over longer durations.

Jubilant Ingrevia Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 0.4%<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was -7.6%, the dividend return was 0.38%, resulting in a total return of -7.22%.<BR><BR>In the 6-month period, the price return was -14.16%, the dividend return was 0.36%, leading to a total return of -13.8%.<BR><BR>Over the 1-year period, the price return was -14.99%, the dividend return was 0.71%, culminating in a total return of -14.28%.<BR><BR>For the 2-year period, the price return was 40.7%, the dividend return was 2.08%, resulting in a total return of 42.78%.<BR><BR>In the 3-year period, the price return was 27.88%, the dividend return was 3.28%, leading to a total return of 31.16%.<BR><BR>During the 4-year period, the price return was 2.93%, the dividend return was 3.51%, resulting in a total return of 6.44%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>Overall, Jubilant Ingrevia Ltd has declared a significant dividend, but the recent total returns over shorter periods indicate a decline in price performance. However, over longer periods, the company has shown positive total returns, suggesting potential recovery and growth.

When is the next results date for Jubilant Ingrevia Ltd?

The next results date for Jubilant Ingrevia Ltd is February 4, 2026.

The next results date for Jubilant Ingrevia Ltd is scheduled for February 4, 2026.

How has been the historical performance of Jubilant Ingrev.?

Jubilant Ingrev. has shown fluctuating financial performance, with net sales of 4,177.61 Cr in March 2025, up from 4,135.80 Cr in March 2024 but down from 4,772.69 Cr in March 2023. Key metrics like operating profit and profit after tax increased from the previous year but remained lower than in March 2023.

Answer:<BR>The historical performance of Jubilant Ingrev. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Ingrev. reported net sales of 4,177.61 Cr in March 2025, a slight increase from 4,135.80 Cr in March 2024, but a decrease from 4,772.69 Cr in March 2023. The total operating income followed a similar pattern, with figures of 4,177.61 Cr in March 2025 and 4,135.80 Cr in March 2024, compared to 4,772.69 Cr in March 2023. The total expenditure, excluding depreciation, was 3,658.53 Cr in March 2025, down from 3,714.68 Cr in March 2024 and 4,225.55 Cr in March 2023. Operating profit (PBDIT) for March 2025 was 556.90 Cr, an increase from 456.42 Cr in March 2024, but lower than 580.51 Cr in March 2023. Profit before tax was 343.63 Cr in March 2025, up from 267.59 Cr in March 2024, but down from 436.75 Cr in March 2023. The profit after tax for March 2025 was 251.19 Cr, an increase from 182.87 Cr in March 2024, but lower than 307.54 Cr in March 2023. The consolidated net profit for March 2025 was 251.17 Cr, compared to 182.89 Cr in March 2024 and 307.50 Cr in March 2023. The earnings per share (EPS) rose to 15.89 in March 2025 from 11.58 in March 2024, but decreased from 19.34 in March 2023. Total assets increased to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024, while total liabilities also rose to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024. The cash flow from operating activities improved to 508.00 Cr in March 2025 from 429.00 Cr in March 2024, although the net cash outflow for March 2025 was -9.00 Cr, down from a positive inflow of 6.00 Cr in March 2024.

Is Jubilant Ingrev. technically bullish or bearish?

As of November 27, 2025, Jubilant Ingrev. shows a mildly bearish trend, indicated by daily moving averages and bearish KST signals, despite some bullish momentum from weekly MACD and Bollinger Bands.

As of 27 November 2025, the technical trend for Jubilant Ingrev. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing bearish signals on both weekly and monthly time frames. While the weekly MACD and Bollinger Bands suggest some bullish momentum, the overall monthly indicators, including MACD and Dow Theory, remain mildly bearish. The stock's recent performance, with a decline of 1.51% over the past week compared to a slight gain in the Sensex, further supports the bearish sentiment.

Is Jubilant Ingrev. overvalued or undervalued?

As of November 7, 2025, Jubilant Ingrev. is considered overvalued with a valuation grade shift to expensive, reflected in its high PE Ratio of 36.66 and underperformance against the Sensex, with a year-to-date return of -19.49%.

As of 7 November 2025, the valuation grade for Jubilant Ingrev. has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 36.66, an EV to EBITDA of 19.92, and a Price to Book Value of 3.61, which are significantly higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla stands at a more attractive PE Ratio of 22.33 and an EV to EBITDA of 5.58. This suggests that Jubilant Ingrev. is trading at a premium relative to its industry peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -19.49% compared to the Sensex's 6.50%, further reinforcing the view that it is overvalued at its current price of 662.90.

Who are the top shareholders of the Jubilant Ingrev.?

The top shareholders of Jubilant Ingrev. include promoters holding 20.63%, mutual funds with 14.1%, foreign institutional investors at 7.12%, and individual investors owning 19.13%, with Dsp Small Cap Fund being the largest public shareholder at 9.37%.

The top shareholders of Jubilant Ingrev. include a mix of promoters, mutual funds, foreign institutional investors (FIIs), and individual investors. The majority shareholders are the promoters, with the highest holding attributed to Spb Trustee Company Pl & Ss Trustee Company Pl, which holds 20.63%. <BR><BR>In terms of mutual funds, 18 schemes collectively hold 14.1% of the company. Foreign institutional investors have a stake of 7.12%, held by 116 different FIIs. The highest public shareholder is Dsp Small Cap Fund, which holds 9.37%. Additionally, individual investors collectively own 19.13% of the company.